Amylin — a peptide hormone co-released with insulin — is deficient in both type 1 and type 2 diabetes, and its synthetic replacement pramlintide improves blood sugar control and promotes weight loss when added to insulin therapy.
3 mechanisms of blood sugar controlAmylin suppresses glucagon, slows stomach emptying, and activates satiety centers — all absent or diminished in diabetes
What the researchers found
Amylin plays three key roles in glucose homeostasis: suppressing post-meal glucagon release, delaying gastric emptying, and activating satiety centers in the brain to reduce caloric intake. Type 1 diabetes patients have absent amylin response to meals, while insulin-requiring type 2 patients have diminished response proportional to beta-cell impairment.
Pramlintide, the synthetic amylin analog, demonstrated significant HbA1c reductions in both type 1 and type 2 diabetes when added to insulin therapy, with favorable effects on body weight — an important advantage since insulin itself tends to promote weight gain. Key risks include increased hypoglycemia when combined with insulin and gastrointestinal side effects including nausea.
Why it matters
Diabetes treatment has traditionally focused almost entirely on insulin, but this review highlights that diabetes involves multiple hormonal deficiencies — including amylin. Replacing amylin alongside insulin provides a more complete hormonal restoration that improves glucose control and addresses the weight gain problem that plagues insulin therapy. Understanding amylin's role has also influenced the development of newer combination approaches like cagrilintide (an amylin analog) paired with semaglutide.
The numbers in context
Amylin absent in T1D; diminished in insulin-requiring T2D; pramlintide reduces A1C and body weight as adjunct to insulin
How the study worked
Narrative review of amylin physiology, pathophysiology in diabetes, and clinical evidence for pramlintide use in type 1 and type 2 diabetes. Published in a diabetes education journal.
Who was studied
Review covering amylin physiology and pramlintide use in adults with type 1 and type 2 diabetes
What this study cannot tell us
Narrative review, not systematic; no specific effect sizes reported; predates newer amylin analog developments; aimed at educators rather than researchers.
How to read the evidence
This is a narrative review in a diabetes education journal that summarizes established physiology and clinical trial data. It serves as a reference-grade overview rather than presenting new primary evidence.
When this study was published
Published in 2015, this review covers well-established amylin physiology and pramlintide clinical data that remain accurate. However, the field has since advanced with newer amylin analogs like cagrilintide entering clinical trials in combination with GLP-1 agonists.
The bigger picture
This review places amylin in the broader context of multi-hormonal diabetes management. The concept of amylin deficiency has gained renewed interest with the development of cagrilintide (a long-acting amylin analog) being combined with semaglutide (CagriSema) for obesity and diabetes treatment. Understanding amylin's foundational role helps explain why these combination approaches are so promising.
Questions still open
- Could long-acting amylin analogs like cagrilintide overcome the practical barriers that limited pramlintide adoption?
- Does amylin replacement early in type 2 diabetes slow beta-cell decline?
- How does amylin's satiety effect compare to GLP-1 agonists, and what's the benefit of combining both?
Common questions
What is amylin and why haven't I heard of it?
Is pramlintide the same as the amylin in CagriSema?
Read the original research
Role of Amylin in Type 1 and Type 2 Diabetes.
The Diabetes educator, 41(1 Suppl), 47S-56S
Citation
Hieronymus, Laura; Griffin, Stacy. (2015). Role of Amylin in Type 1 and Type 2 Diabetes.. The Diabetes educator, 41(1 Suppl), 47S-56S. https://doi.org/10.1177/0145721715607642